Prexton Therapeutics

Recent Events

View All
Bio-Europe 2016 in Stockholm
Bio-Europe 2016 in Stockholm

Link to official website

Learn More
BioEquity 2016 in Copenhagen
BioEquity 2016 in Copenhagen

Learn More
Prexton opts for Parkinson drug
Prexton opts for Parkinson dru ...

23.01.2013 - Merck-Serono spin-out Prexton Therapeutics has secured an exclusive licence o ...

Learn More
J.P. MORGAN HEALTHCARE CONFERENCE
J.P. MORGAN HEALTHCARE CONFERE ...

January 7-10, 2013. Prexton Therapeutics will be present at the 31st Annual J.P. Morgan H ...

Learn More

Last Press Release

View All
Maladie de Parkinson : Prexton Therapeutics finalise son essai clinique de phase 1
Maladie de Parkinson : Prexton ...

L’étude montre que le modulateur allostérique positif mGluR4 est sûr et bien toléré ...

Learn More
Parkinson’s disease: Prexton Therapeutics starts phase 1 clinical trial
Parkinson’s disease: Prexton ...

First clinical trial with an mGluR4 positive allosteric modulator, a first-in-class compou ...

Learn More
Prexton Therapeutics raises 8.7 million euros (10 million dollars) in a Series A round
Prexton Therapeutics raises 8. ...

Swiss based startup attracts venture funding from leading European VC firms to addres ...

Learn More
PREXTON THERAPEUTICS ANNOUNCE
PREXTON THERAPEUTICS ANNOUNCE

January 22, 2013. Prexton Therapeutics will  develop novel mGluR4 PAM series, via an ...

Learn More
Merck Serono Announce
Merck Serono Announce

July 30, 2012. Merck Serono announces the creation of the first spin-off company “Prexto ...

Learn More